Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis (PPMS), linking its BTK inhibitor to a 12% reduction in the risk of disability progression compared to Ocrevus.
- Home |
- Roche unveils data behind BTK inhibitor’s phase 3 multiple sclerosis win in Ocrevus trial
Roche unveils data behind BTK inhibitor’s phase 3 multiple sclerosis win in Ocrevus trial
- February 9, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
